[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 10
1. Hille A, Ott I, Kitanovic A, Kitanovic I, Alborzinia H, Lederer E, Wölfl S, Metzler-Nolte N, Schäfer S, Sheldrick WS, Bischof C, Schatzschneider U, Gust R: [N,N'-Bis(salicylidene)-1,2-phenylenediamine]metal complexes with cell death promoting properties. J Biol Inorg Chem; 2009 Jun;14(5):711-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We developed N,N'-bis(salicylidene)-1,2-phenylenediamine (salophene, 1) as a chelating agent for metal ions such as Mn(II/III), Fe(II/III), Co(II), Ni(II), Cu(II), and Zn(II).
  • [MeSH-major] Apoptosis / drug effects. Chelating Agents / chemistry. Chelating Agents / pharmacology. Metals / chemistry. Salicylates / chemistry. Salicylates / pharmacology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Animals. Breast Neoplasms / drug therapy. Carcinoma / drug therapy. Cattle. Cell Line, Tumor. Circular Dichroism. Colonic Neoplasms / drug therapy. DNA / metabolism. Electric Impedance. Female. Humans. Oxidation-Reduction. Oxygen Consumption / drug effects. Reactive Oxygen Species / metabolism. Thymus Gland / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathophysiology. 2000 Sep;7(3):153-163 [10996508.001]
  • [Cites] J Med Chem. 2004 Nov 18;47(24):5837-46 [15537341.001]
  • [Cites] Inorg Chem. 1996 Aug 14;35(17):4837-4847 [11666683.001]
  • [Cites] Curr Med Chem. 2005;12(10):1161-208 [15892631.001]
  • [Cites] Biosens Bioelectron. 1997;12(1):29-41 [8976050.001]
  • [Cites] J Cancer Res Clin Oncol. 1992;118(1):35-43 [1309532.001]
  • [Cites] ChemMedChem. 2007 Dec;2(12):1723-9 [17943711.001]
  • [Cites] Mol Cell Biochem. 2004 Nov;266(1-2):37-56 [15646026.001]
  • [Cites] J Fluoresc. 2005 Jan;15(1):13-9 [15711872.001]
  • [Cites] Fresenius J Anal Chem. 2001 Jan 1;369(1):30-5 [11210226.001]
  • [Cites] Nature. 1995 Jul 6;376(6535):37-43 [7596430.001]
  • [Cites] Bioconjug Chem. 1997 Nov-Dec;8(6):798-812 [9404652.001]
  • [Cites] Cancer Treat Rev. 2007 Jun;33(4):347-57 [17383100.001]
  • [Cites] Chem Commun (Camb). 2007 Nov 28;(44):4565-79 [17989802.001]
  • [Cites] J Inorg Biochem. 1996 Jun;62(4):281-98 [8676105.001]
  • [Cites] J Cancer Res Clin Oncol. 1988;114(4):347-58 [3410875.001]
  • [Cites] J Biol Chem. 1998 Dec 11;273(50):33533-9 [9837934.001]
  • [Cites] Nature. 1992 Mar 26;356(6367):356-8 [1549180.001]
  • [Cites] J Am Chem Soc. 2005 Aug 10;127(31):10869-78 [16076192.001]
  • [Cites] Chem Soc Rev. 2003 Jul;32(4):215-24 [12875027.001]
  • [Cites] Nature. 1994 Sep 22;371(6495):346-7 [8090205.001]
  • [Cites] Chem Rev. 1999 Sep 8;99(9):2777-96 [11749500.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1558-77 [15073842.001]
  • [Cites] Chem Rev. 2001 Jan;101(1):37-52 [11712193.001]
  • [Cites] J Med Chem. 2002 Sep 26;45(20):4549-58 [12238934.001]
  • [Cites] Cell. 1995 Jun 2;81(5):801-9 [7774019.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Apr 1;220(1):33-44 [17320130.001]
  • [Cites] Anal Biochem. 1990 Jun;187(2):262-7 [2382827.001]
  • [Cites] Chemistry. 2005 Aug 5;11(16):4743-50 [15912543.001]
  • [Cites] Methods Enzymol. 1990;186:1-85 [2172697.001]
  • [Cites] Biochem J. 1997 Aug 15;326 ( Pt 1):1-16 [9337844.001]
  • (PMID = 19259708.001).
  • [ISSN] 1432-1327
  • [Journal-full-title] Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry
  • [ISO-abbreviation] J. Biol. Inorg. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chelating Agents; 0 / Metals; 0 / Reactive Oxygen Species; 0 / Salicylates; 118-57-0 / salophen; 9007-49-2 / DNA
  •  go-up   go-down


2. Pakhrin B, Kang MS, Bae IH, Park MS, Jee H, You MH, Kim JH, Yoon BI, Choi YK, Kim DY: Retrospective study of canine cutaneous tumors in Korea. J Vet Sci; 2007 Sep;8(3):229-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Out of these, 748 (25.34%) cases were diagnosed as canine cutaneous tumors in the Department of Veterinary Pathology, College of Veterinary Medicine, Seoul National University, Korea.
  • The top ten most frequently diagnosed cutaneous tumors were epidermal and follicular cysts (12.70%), lipoma (11.36%), mast cell tumors (8.82%), cutaneous histiocytoma (7.49%), basal cell tumors (6.82%), sebaceous gland adenoma (6.68%), sebaceous gland hyperplasia (5.08%), hepatoid gland adenoma (3.61%), apocrine adenocarcinoma (3.07%), and fibroma (2.81%), in order of prevalence.
  • These top ten cutaneous tumors were distributed on the trunk (30.08%), head and neck (20.9%), extremities (19.14%), anal and perianal area (8.59%), and tail (3.91%).
  • [MeSH-minor] Animals. Biopsy / veterinary. Dogs. Female. Immunohistochemistry / veterinary. Korea / epidemiology. Male. Prevalence. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Vet Med A Physiol Pathol Clin Med. 2002 Mar;49(2):87-91 [11958472.001]
  • [Cites] Adv Vet Sci Comp Med. 1970;14:309-54 [4922146.001]
  • [Cites] Aust Vet J. 1979 Dec;55(12):602-4 [231964.001]
  • [Cites] Aust Vet J. 1983 Mar;60(3):87-8 [6603213.001]
  • [Cites] J Vet Diagn Invest. 2006 Jul;18(4):422-5 [16921890.001]
  • [Cites] Br Vet J. 1986 Jan-Feb;142(1):1-19 [3947927.001]
  • [Cites] Aust Vet J. 1987 Jun;64(6):161-4 [3115242.001]
  • [Cites] J Am Vet Med Assoc. 1992 May 15;200(10):1530-2 [1612996.001]
  • [Cites] Vet Clin North Am Small Anim Pract. 1985 May;15(3):473-92 [3874467.001]
  • (PMID = 17679768.001).
  • [ISSN] 1229-845X
  • [Journal-full-title] Journal of veterinary science
  • [ISO-abbreviation] J. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2868128
  •  go-up   go-down


3. Bennett PF, DeNicola DB, Bonney P, Glickman NW, Knapp DW: Canine anal sac adenocarcinomas: clinical presentation and response to therapy. J Vet Intern Med; 2002 Jan-Feb;16(1):100-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canine anal sac adenocarcinomas: clinical presentation and response to therapy.
  • A retrospective study of 43 dogs with anal sac adenocarcinoma (ASAC) was performed to characterize the clinical presentation and response to treatment.
  • A variety of chemotherapeutic agents were administered, with partial remission (PR) recorded in 4 of 13 (31%) dogs treated with cisplatin and in 1 of 3 (33%) dogs treated with carboplatin.
  • We conclude that platinum chemotherapy has antitumor activity in canine apocrine gland carcinoma and that further study of these agents is warranted.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11822797.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 1CC1JFE158 / Dactinomycin; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. van der Kuip H, Mürdter TE, Sonnenberg M, McClellan M, Gutzeit S, Gerteis A, Simon W, Fritz P, Aulitzky WE: Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer; 2006;6:86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment.
  • BACKGROUND: Sensitivity of breast tumors to anticancer drugs depends upon dynamic interactions between epithelial tumor cells and their microenvironment including stromal cells and extracellular matrix.
  • To study drug-sensitivity within different compartments of an individual tumor ex vivo, culture models directly established from fresh tumor tissues are absolutely essential.
  • CONCLUSION: We describe a tissue culture method combined with a novel read out system for both tissue cultivation and rapid assessment of drug efficacy together with the simultaneous identification of different cell types within non-fixed breast cancer tissues.
  • This method has potential significance for studying tumor responses to anticancer drugs in the complex environment of a primary cancer tissue.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Antineoplastic Agents, Phytogenic / pharmacology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Drug Screening Assays, Antitumor / methods. Paclitaxel / pharmacology
  • [MeSH-minor] Adenosine Triphosphate / analysis. Apoptosis / drug effects. Cell Division / drug effects. Cell Survival. DNA, Neoplasm / analysis. Female. Humans. Microscopy, Confocal. Microscopy, Fluorescence. Tumor Cells, Cultured / chemistry. Tumor Cells, Cultured / drug effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 1998;194(3):177-81 [9587936.001]
  • [Cites] Physiol Rev. 1996 Jan;76(1):69-125 [8592733.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1999 Apr;4(2):193-201 [10426398.001]
  • [Cites] Mol Cell Neurosci. 2005 Jan;28(1):42-54 [15607940.001]
  • [Cites] Toxicol Sci. 2005 Feb;83(2):257-63 [15525692.001]
  • [Cites] Cell Death Differ. 2005 Jun;12(6):627-36 [15818402.001]
  • [Cites] Methods Mol Med. 2005;110:101-20 [15901931.001]
  • [Cites] Biotechnol Prog. 2005 Jul-Aug;21(4):1289-96 [16080713.001]
  • [Cites] Endocr Relat Cancer. 2000 Jun;7(2):95-113 [10903527.001]
  • [Cites] Breast Cancer Res. 2001;3(4):218-23 [11434872.001]
  • [Cites] Int J Cancer. 2002 Jan 10;97(2):186-94 [11774263.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):205-16 [12242153.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):537-46 [12492495.001]
  • [Cites] Breast Cancer Res. 2003;5(2):89-95 [12631387.001]
  • [Cites] J Cell Sci. 2003 Jun 15;116(Pt 12):2377-88 [12766184.001]
  • [Cites] Drug Resist Updat. 2003 Aug;6(4):169-72 [12962682.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1789-95 [14583785.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1751-6 [14996736.001]
  • [Cites] Breast Cancer Res Treat. 2004 Jun;85(3):281-91 [15111767.001]
  • [Cites] Oncol Rep. 2004 Jul;12(1):85-90 [15201964.001]
  • [Cites] Neoplasma. 1967;14(5):507-19 [5583355.001]
  • [Cites] Anal Biochem. 1980 May 1;104(1):118-23 [6770714.001]
  • [Cites] Biomed Biochim Acta. 1983;42(7-8):907-16 [6316948.001]
  • [Cites] Ann N Y Acad Sci. 1986;464:58-65 [2942075.001]
  • [Cites] Cancer Drug Deliv. 1987;4(2):63-74 [3427553.001]
  • [Cites] Cancer Res. 1990 Jan 1;50(1):78-83 [2293560.001]
  • [Cites] Blood. 1990 Jun 15;75(12):2417-26 [1693532.001]
  • [Cites] Nat Med. 1999 Jun;5(6):662-8 [10371505.001]
  • (PMID = 16603054.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / DNA, Neoplasm; 8L70Q75FXE / Adenosine Triphosphate; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC1456977
  •  go-up   go-down


5. Bartusik D, Tomanek B, Siluk D, Kaliszan R, Fallone G: The application of 19F magnetic resonance ex vivo imaging of three-dimensional cultured breast cancer cells to study the effect of delta-tocopherol. Anal Biochem; 2009 Apr 15;387(2):315-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human gland mammary adenocarcinoma (MCF-7) and human T-lymphoblastoid (CEM) cells were cultured in the presence of delta-tocopherol at various concentrations (0-750 microM) for 5 days.
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Female. Fluorine. Humans. Oxygen / analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. FLUORINE .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19454246.001).
  • [ISSN] 1096-0309
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1406-66-2 / Tocopherols; 284SYP0193 / Fluorine; JU84X1II0N / delta-tocopherol; S88TT14065 / Oxygen
  •  go-up   go-down


6. de Noo ME, Tollenaar RA, Deelder AM, Bouwman LH: Current status and prospects of clinical proteomics studies on detection of colorectal cancer: hopes and fears. World J Gastroenterol; 2006 Nov 7;12(41):6594-601
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal adenocarcinoma (CRC) is the third most common type of cancer and the fourth most frequent cause of death due to cancer worldwide.
  • Given the natural history of CRC, early diagnosis appears to be the most appropriate tool to reduce disease-related mortality.
  • (1) proteins being abnormally produced or shed and added to the serum proteome, (2) proteins clipped or modified as a consequence of the disease process, or (3) proteins subtracted from the proteome owing to disease-related proteolytic degradation pathways.
  • This paper focuses on the current status of clinical proteomics research in oncology and in colorectal cancer especially, and will reflect on pitfalls and fears in this relatively new area of clinical medicine, which are reproducibility issues and pre-analytical factors, statistical issues, and identification and nature of discriminating proteins/peptides.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colorectal Neoplasms / diagnosis. Proteomics / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2002 Dec;126(12):1518-26 [12456215.001]
  • [Cites] Proteomics. 2003 Jan;3(1):56-63 [12548634.001]
  • [Cites] Clin Chem. 2006 Jun;52(6):1045-53 [16574760.001]
  • [Cites] Semin Oncol. 2005 Feb;32(1):24-34 [15726503.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):233-7 [12634797.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):489-90; author reply 490-1 [12644546.001]
  • [Cites] Eur J Cancer. 2003 Apr;39(6):718-27 [12651195.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):243-52 [12671663.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):267-75 [12671665.001]
  • [Cites] J Am Coll Surg. 2003 May;196(5):722-8 [12742204.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Oct;7(4):433-40 [12882527.001]
  • [Cites] Bioinformatics. 2003 Aug 12;19(12):1484-91 [12912828.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2904-11 [12912935.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Trends Biotechnol. 2002 Dec;20(12 Suppl):S30-4 [12570157.001]
  • [Cites] Technol Cancer Res Treat. 2002 Aug;1(4):297-304 [12625789.001]
  • [Cites] Anal Chem. 2005 Nov 15;77(22):7232-41 [16285670.001]
  • [Cites] Clin Chem. 2005 Dec;51(12):2229-35 [16223889.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):845-56 [16239904.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):26-30 [16395400.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):271-84 [16395409.001]
  • [Cites] J Pathol. 2006 Apr;208(5):595-606 [16518808.001]
  • [Cites] Proteomics. 2006 Apr;6(7):2095-100 [16502467.001]
  • [Cites] World J Gastroenterol. 2006 Mar 14;12(10):1536-44 [16570345.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1068-76 [16603345.001]
  • [Cites] Biostatistics. 2003 Jul;4(3):449-63 [12925511.001]
  • [Cites] Lancet. 2003 Aug 9;362(9382):433-9 [12927430.001]
  • [Cites] J Proteome Res. 2003 Jul-Aug;2(4):361-72 [12938926.001]
  • [Cites] Proteomics. 2003 Sep;3(9):1667-72 [12973722.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6105-9 [14559785.001]
  • [Cites] BMC Bioinformatics. 2003 Jun 9;4:24 [12795817.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):353-6 [14996856.001]
  • [Cites] Anal Chem. 2004 Mar 15;76(6):1560-70 [15018552.001]
  • [Cites] Bioinformatics. 2004 Mar 22;20(5):777-85 [14751995.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):309-14 [15057290.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1448-53 [15131804.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2375-82 [15175439.001]
  • [Cites] World J Gastroenterol. 2004 Nov 1;10(21):3127-31 [15457557.001]
  • [Cites] Ann Intern Med. 1997 May 15;126(10):811-22 [9148658.001]
  • [Cites] Eur J Cancer. 2004 Nov;40(17):2613-22 [15541962.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):16-22 [15598930.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):378-91 [15637400.001]
  • [Cites] Lancet. 2005 Jan 8-14;365(9454):153-65 [15639298.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):963-5 [15709159.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1110-8 [15709178.001]
  • [Cites] Nat Biotechnol. 2005 Mar;23(3):291-2 [15765078.001]
  • [Cites] BMC Bioinformatics. 2005;6:68 [15788095.001]
  • [Cites] Brief Funct Genomic Proteomic. 2005 Feb;3(4):322-31 [15814023.001]
  • [Cites] Clin Sci (Lond). 2005 May;108(5):369-83 [15831087.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1685-95 [15887159.001]
  • [Cites] Clin Chem. 2005 Jun;51(6):973-80 [15845803.001]
  • [Cites] Am J Gastroenterol. 2005 Jun;100(6):1393-403 [15929776.001]
  • [Cites] Rapid Commun Mass Spectrom. 2005;19(12):1624-36 [15915451.001]
  • [Cites] J Proteome Res. 2005 May-Jun;4(3):972-81 [15952745.001]
  • [Cites] Anal Chem. 2005 Aug 15;77(16):5114-23 [16097747.001]
  • [Cites] Dig Surg. 2005;22(4):276-81 [16174984.001]
  • [Cites] Adv Exp Med Biol. 2000;477:349-78 [10849763.001]
  • [Cites] J Pathol. 2000 Nov;192(3):280-8 [11054709.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2002 Jan;12(1):53-63 [11916161.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):872-9 [11978511.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3609-14 [12097261.001]
  • [Cites] Ann Intern Med. 2002 Jul 16;137(2):132-41 [12118972.001]
  • [Cites] Lancet. 2002 Jul 13;360(9327):170; author reply 170-1 [12126845.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1160-9 [12142368.001]
  • (PMID = 17075970.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 69
  • [Other-IDs] NLM/ PMC4125662
  •  go-up   go-down


7. Michimukai E, Kitamura N, Zhang Y, Wang H, Hiraishi Y, Sumi K, Hayashido Y, Toratani S, Okamoto T: Mutations in the human homologue of the Drosophila segment polarity gene patched in oral squamous cell carcinoma cell lines. In Vitro Cell Dev Biol Anim; 2001 Jul-Aug;37(7):459-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found two missense mutations which affected the conserved residue in the transmembrane domains of the gene product and in the intracellular loop at the C-terminal residue implicated in regulating the smoothened molecule.
  • In addition, we demonstrated that the N-terminal fragment of sonic hedgehog (Shh-N) stimulates the growth of normal epithelial cells, the OSCC cell line, NA, and the salivary gland adenocarcinoma cell lines, HSG and HSY, which have no detectable mutation in patched.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. DNA, Neoplasm / analysis. Membrane Proteins / genetics. Mouth Neoplasms / genetics. Mutation
  • [MeSH-minor] Cell Division / drug effects. Culture Media, Serum-Free. DNA Mutational Analysis. Epithelial Cells / drug effects. Hedgehog Proteins. Humans. Mutation, Missense. Patched Receptors. Peptide Fragments / pharmacology. Polymorphism, Single-Stranded Conformational. RNA, Messenger / analysis. Receptors, Cell Surface. Sequence Analysis, DNA. Signal Transduction. Trans-Activators / pharmacology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1997 Aug 22;277(5329):1109-13 [9262482.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] J Oral Pathol Med. 1994 Nov;23(10):451-6 [7532220.001]
  • [Cites] Oncogene. 1997 Jul 17;15(3):361-6 [9233770.001]
  • [Cites] Nat Genet. 1996 Sep;14 (1):7-8 [8782809.001]
  • [Cites] Nature. 1980 Oct 30;287(5785):795-801 [6776413.001]
  • [Cites] Nature. 1996 Nov 14;384(6605):129-34 [8906787.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Trends Cell Biol. 1997 Nov;7(11):442-6 [17709003.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Sep 18;238(2):658-64 [9299570.001]
  • [Cites] Nat Genet. 1996 Sep;14 (1):78-81 [8782823.001]
  • [Cites] EMBO J. 1998 Jul 1 ;17 (13):3505-11 [9649421.001]
  • [Cites] Nature. 1996 Nov 14;384(6605):176-9 [8906794.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1986;51(3):187-95 [2426861.001]
  • [Cites] Cell. 1994 Feb 25;76(4):761-75 [8124714.001]
  • [Cites] Nat Med. 1995 Nov;1(11):1184-8 [7584992.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4677-81 [9354420.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1417-30 [7916661.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16778-85 [1885605.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):842-5 [9041183.001]
  • [Cites] Mol Med Today. 1998 Aug;4(8):343-9 [9755453.001]
  • [Cites] Nature. 1997 Oct 23;389(6653):876-81 [9349822.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Science. 1994 Dec 2;266(5190):1528-37 [7985023.001]
  • [Cites] Proc Natl Acad Sci U S A. 1977 Feb;74(2):565-9 [265522.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2369-72 [9192811.001]
  • [Cites] Trends Genet. 1997 Jan;13(1):14-21 [9009843.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1401-16 [8269518.001]
  • [Cites] In Vitro Cell Dev Biol. 1988 Aug;24(8):753-8 [3045071.001]
  • [Cites] Cancer. 1981 Aug 1;48(3):745-52 [7248901.001]
  • [Cites] Science. 1997 May 2;276(5313):817-21 [9115210.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1995 Feb;31(2):84-6 [7735570.001]
  • [Cites] Cell. 1995 Feb 24;80(4):517-20 [7867057.001]
  • [Cites] J Natl Cancer Inst. 1997 Aug 6;89(15):1103-9 [9262247.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Aug;85(15):5698-702 [3165197.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Mar;21(3):276-9 [9523206.001]
  • [Cites] Dermatol Clin. 1995 Jan;13(1):113-25 [7712637.001]
  • [Cites] Cell. 1992 Apr 3;69(1):111-7 [1348213.001]
  • (PMID = 11573822.001).
  • [ISSN] 1071-2690
  • [Journal-full-title] In vitro cellular & developmental biology. Animal
  • [ISO-abbreviation] In Vitro Cell. Dev. Biol. Anim.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Culture Media, Serum-Free; 0 / DNA, Neoplasm; 0 / Hedgehog Proteins; 0 / Membrane Proteins; 0 / Patched Receptors; 0 / Peptide Fragments; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / SHH protein, human; 0 / Trans-Activators
  •  go-up   go-down


8. Venclauskas L, Saladzinskas Z, Tamelis A, Pranys D, Pavalkis D: Mucinous adenocarcinoma arising in an anorectal fistula. Medicina (Kaunas); 2009;45(4):286-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma arising in an anorectal fistula.
  • Mucinous adenocarcinoma in association with chronic anal fistula is a rare case in clinical practice.
  • The aim of this article was to report a rare case of anal gland mucinous adenocarcinoma in a patient who was treated in the Hospital of Kaunas University of Medicine.
  • Histological examination revealed mucinous adenocarcinoma, G2.
  • Histological examination after abdominoperineal resection revealed anal duct mucinous adenocarcinoma pT2 N0 L0 V0 R0, G2.
  • SUMMARY: Mucinous adenocarcinoma in anorectal fistula is a rare condition.
  • If surgical treatment for perineal abscess or anorectal fistula is not successful for a long time, mucinous adenocarcinoma should be suspected.
  • [MeSH-major] Adenocarcinoma, Mucinous. Anus Neoplasms. Rectal Fistula / complications
  • [MeSH-minor] Abscess / complications. Aged. Anal Canal / pathology. Humans. Male. Neoplasm Staging. Perineum

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19423959.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Lithuania
  •  go-up   go-down


9. Delgado JS, Mustafi R, Yee J, Cerda S, Chumsangsri A, Dougherty U, Lichtenstein L, Fichera A, Bissonnette M: Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells. Dig Dis Sci; 2008 Dec;53(12):3055-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells.
  • BACKGROUND AND PURPOSE: Current therapies offer scant benefit to patients with advanced esophageal adenocarcinoma.
  • We investigated the effects of Sorafenib, a multifunctional kinase inhibitor, on several growth regulatory pathways that control cell growth and survival in SEG-1 cells derived from Barrett's adenocarcinoma.
  • This drug significantly reduced the up-regulations of cyclin D1, cyclin E, c-Myc, and Bcl-2 as well as the activation of STAT3 in SEG-1 cells.
  • CONCLUSIONS: These results support a rational basis for future clinical studies to assess the therapeutic benefit of Sorafenib in esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Benzenesulfonates / pharmacology. Cell Proliferation / drug effects. Esophageal Neoplasms / pathology. Pyridines / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Cyclin D1 / metabolism. Cyclin E / metabolism. Extracellular Signal-Regulated MAP Kinases / metabolism. Humans. Niacinamide / analogs & derivatives. Phenylurea Compounds. Proto-Oncogene Proteins c-akt / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-myc / metabolism. STAT3 Transcription Factor / metabolism. p38 Mitogen-Activated Protein Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Pharmacol. 2007 May 1;73(9):1308-17 [17266941.001]
  • [Cites] Gut. 1989 Jan;30(1):14-8 [2920919.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4819-25 [14581353.001]
  • [Cites] Gastroenterology. 1984 Oct;87(4):927-33 [6468881.001]
  • [Cites] ANZ J Surg. 2007 Jan-Feb;77(1-2):37-9 [17295818.001]
  • [Cites] Dis Esophagus. 2007;20(3):212-6 [17509117.001]
  • [Cites] Oncol Rep. 1999 Jul-Aug;6(4):877-82 [10373674.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):299-307 [11832445.001]
  • [Cites] Eur J Cancer. 2005 Mar;41(5):664-72 [15763640.001]
  • [Cites] Eur J Surg Oncol. 2007 Apr;33(3):307-13 [17123775.001]
  • [Cites] Oncogene. 2003 Oct 30;22(49):7809-18 [14586407.001]
  • [Cites] Histopathology. 2001 Dec;39(6):589-96 [11903577.001]
  • [Cites] Gut. 2005 Mar;54 Suppl 1:i6-12 [15711008.001]
  • [Cites] Br J Surg. 2002 Jul;89(7):824-37 [12081731.001]
  • [Cites] Surgery. 2004 Aug;136(2):160-8 [15300175.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3291-310 [17496923.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2006 Jan;11(1):75-87 [16947086.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6771-90 [16170185.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 May;4(5):566-72 [16630761.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5656-64 [16740703.001]
  • [Cites] Anal Biochem. 2000 Oct 15;285(2):194-204 [11017702.001]
  • [Cites] EMBO J. 2000 Nov 1;19(21):5813-23 [11060032.001]
  • [Cites] Gut. 1991 Dec;32(12):1441-6 [1773946.001]
  • [Cites] Am J Gastroenterol. 1997 Feb;92(2):212-5 [9040193.001]
  • [Cites] Mol Cell Biol. 2000 May;20(10):3497-509 [10779339.001]
  • [Cites] BMC Cancer. 2007 Jun 08;7:97 [17559672.001]
  • [Cites] J Natl Med Assoc. 2007 Jun;99(6):620-6 [17595930.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Oct;287(4):G743-8 [15231484.001]
  • [Cites] Oncol Rep. 2007 Jun;17(6):1377-82 [17487394.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2544-52 [16510571.001]
  • [Cites] Dis Esophagus. 2008;21(6):514-21 [18840136.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Feb 15;25(4):447-53 [17270000.001]
  • [Cites] Gut. 2003 Feb;52(2):174-80 [12524396.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Feb;290(2):G335-42 [16239404.001]
  • [Cites] J Surg Res. 2005 Jul 1;127(1):53-8 [15964304.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Nat Rev Drug Discov. 2006 Oct;5(10):835-44 [17016424.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1028-32 [9672324.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3227-39 [17496918.001]
  • [Cites] JAMA. 2001 May 9;285(18):2331-8 [11343480.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11851-8 [17178882.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):379-88 [11331954.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5305-13 [17875759.001]
  • [Cites] J Clin Pathol. 2006 Jun;59(6):631-4 [16731604.001]
  • [Cites] Semin Oncol. 2007 Apr;34(2 Suppl 1):S2-6 [17449347.001]
  • [Cites] Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004063 [17054195.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21 [10944553.001]
  • (PMID = 18512153.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA036745; United States / NIDDK NIH HHS / DK / P30DK42086
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Cyclin E; 0 / MYC protein, human; 0 / Phenylurea Compounds; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc; 0 / Pyridines; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 136601-57-5 / Cyclin D1; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


10. Bauer JA, Frye G, Bahr A, Gieg J, Brofman P: Anti-tumor effects of nitrosylcobalamin against spontaneous tumors in dogs. Invest New Drugs; 2010 Oct;28(5):694-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Given the limited options available to treat canine cancers, the use of companion animals for evaluating new drugs may identify better therapies for veterinary and human oncology.
  • (1) A 13 year-old female spayed Giant Schnauzer with inoperable thyroid carcinoma and hypercalcemia. (2) A 6 year-old male neutered Golden Retriever with a malignant peripheral nerve sheath tumor (MPNST). (3) A ten yr-old neutered male Bichon Frise with apocrine gland anal sac adenocarcinoma (AGACA). (4) A 7 year-old female spayed Labrador mix with spinal meningioma following partial surgical resection.
  • [MeSH-major] Dog Diseases / drug therapy. Neoplasms / veterinary. Nitroso Compounds / therapeutic use. Vitamin B 12 / analogs & derivatives
  • [MeSH-minor] Animals. Antineoplastic Agents / metabolism. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Dogs. Dose-Response Relationship, Drug. Female. Magnetic Resonance Imaging. Male. Tumor Burden. Ultrasonography

  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Invest New Drugs. 2011 Oct;29(5):1122
  • [Cites] Eur J Cancer. 2004 Apr;40(6):858-80 [15120042.001]
  • [Cites] J Vet Intern Med. 1988 Jan-Mar;2(1):41-6 [3221354.001]
  • [Cites] Nat Med. 2005 Oct;11(10):1018 [16211022.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Jun;23(2):181-93 [15354401.001]
  • [Cites] J Am Vet Med Assoc. 1991 May 1;198(9):1618-21 [2061177.001]
  • [Cites] J Am Anim Hosp Assoc. 1998 Jan-Feb;34(1):19-25 [9527425.001]
  • [Cites] Vet Radiol Ultrasound. 2001 Sep-Oct;42(5):471-4 [11678572.001]
  • [Cites] J Small Anim Pract. 1999 May;40(5):206-10 [10385862.001]
  • [Cites] J Am Vet Med Assoc. 2006 Aug 15;229(4):542-8 [16910854.001]
  • [Cites] J Vet Intern Med. 2002 Jan-Feb;16(1):100-4 [11822797.001]
  • [Cites] Clin Tech Small Anim Pract. 2007 May;22(2):75-81 [17591293.001]
  • [Cites] Brief Funct Genomic Proteomic. 2005 Jul;4(2):112-28 [16102268.001]
  • [Cites] Anticancer Drugs. 1998 Mar;9(3):239-44 [9625434.001]
  • [Cites] J Nucl Med. 1997 May;38(5):717-23 [9170435.001]
  • [Cites] Semin Vet Med Surg (Small Anim). 1996 Nov;11(4):225-34 [9020576.001]
  • [Cites] Aust Vet J. 2005 Jun;83(6):340-3 [15986909.001]
  • [Cites] Cancer Invest. 2000;18(8):781-92 [11107448.001]
  • [Cites] Mayo Clin Proc. 2000 Jun;75(6):568-80 [10852417.001]
  • [Cites] J Am Vet Med Assoc. 1975 Mar 1;166(5):511-7 [1112759.001]
  • [Cites] Aust Vet J. 2005 Apr;83(4):208-14 [15907038.001]
  • [Cites] J Am Anim Hosp Assoc. 1998 Mar-Apr;34(2):109-12 [9507422.001]
  • [Cites] Vet Pathol. 2004 Jul;41(4):307-18 [15232130.001]
  • [Cites] J Am Anim Hosp Assoc. 1997 Jul-Aug;33(4):307-12 [9204465.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 3;94(13):1010-9 [12096086.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):420-30 [12189384.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39461-9 [12881518.001]
  • [Cites] J Am Vet Med Assoc. 1995 Apr 1;206(7):1007-9 [7768706.001]
  • [Cites] J Am Vet Med Assoc. 2003 Sep 15;223(6):825-31 [14507100.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • [Cites] J Vet Intern Med. 1994 May-Jun;8(3):236-9 [8064663.001]
  • [Cites] J Am Anim Hosp Assoc. 1995 Jul-Aug;31(4):349-59 [7552669.001]
  • [Cites] In Vivo. 1994 Jan-Feb;8(1):133-43 [8054503.001]
  • [Cites] Mol Cell Biol. 2006 Aug;26(15):5588-94 [16847314.001]
  • [Cites] J Am Vet Med Assoc. 1989 Dec 1;195(11):1580-3 [2599941.001]
  • [Cites] Vet Comp Oncol. 2003 Jun;1(2):94-104 [19379321.001]
  • [Cites] J Neurosurg Anesthesiol. 1994 Apr;6(2):111-5 [8012169.001]
  • [Cites] J Small Anim Pract. 1981 Mar;22(3):119-28 [7230749.001]
  • [Cites] Vet Surg. 2006 Apr;35(3):267-70 [16635006.001]
  • [Cites] Vet Pathol. 1998 May;35(3):223-6 [9598587.001]
  • [Cites] PLoS One. 2007 Dec 12;2(12):e1313 [18074035.001]
  • [Cites] J Exp Clin Cancer Res. 2006 Mar;25(1):97-105 [16761625.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 1;98(3):161-2 [16449674.001]
  • [Cites] J Am Vet Med Assoc. 1987 Sep 15;191(6):720-6 [3679964.001]
  • (PMID = 19557306.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA095020
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitroso Compounds; 0 / nitrosylcobalamin; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down






Advertisement